Skip to content

A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP.

Anna Johansson, Daniel Lindstedt, Markus Roman, Gunilla Thelander, Elisabet I Nielsen, Ulrica Lennborn, Håkan Sandler, Sten Rubertsson, Johan Ahlner, Robert Kronstrand, Fredrik C Kugelberg

Forensic science international June 1, 2017 DOI: 10.1016/j.forsciint.2017.02.034 via PubMed

Summary

AI-generated from the abstract

3-Methoxyphencyclidine (3-MeO-PCP), a phencyclidine analogue with anesthetic, analgesic, and hallucinogenic properties, appeared on the illicit drug market in 2011. This paper reports a non-fatal intoxication and seven deaths involving 3-MeO-PCP in Sweden from March 2014 to June 2016. The non-fatal case involved a 19-year-old male with drug problems and depression who presented awake but tachycardic, hypertensive, tachypnoeic, and catatonic, later developing fever, lactic acidosis, psychomotor agitation, and hallucinations; he fully recovered after 22 hours of intensive care. Blood concentrations of 3-MeO-PCP at admission were 0.14 μg/g, declining to 0.04 μg/g after 17 hours, with an estimated half-life of 11 hours.

Study at a glance

Characteristics Case series Case report Peer reviewed
Sample size 8
Population Individuals in Sweden with 3-MeO-PCP intoxication or death, March 2014–June 2016
Keywords 3-meo-pcp Dissociative drugs Intoxication Phencyclidine Postmortem blood concentrations
Key finding 3-MeO-PCP intoxication can cause severe adverse events and death, with femoral blood concentrations ranging from 0.05 μg/g to 0.38 μg/g in fatal cases and an estimated half-life of 11 hours.

Abstract

3-methoxyphencyclidine (3-MeO-PCP) appeared on the illicit drug market in 2011 and is an analogue of phencyclidine, which exhibits anesthetic, analgesic and hallucinogenic properties. In this paper, we report data from a non-fatal intoxication and seven deaths involving 3-MeO-PCP in Sweden during the period March 2014 until June 2016. The non-fatal intoxication case, a 19-year-old male with drug problems and a medical history of depression, was found awake but tachycardic, hypertensive, tachypnoeic and catatonic at home. After being hospitalized, his condition worsened as he developed a fever and lactic acidosis concomitant with psychomotor agitation and hallucinations. After 22h of intensive care, the patient had made a complete recovery. During his hospitalization, a total of four blood samples were collected at different time points. The seven autopsy cases, six males and one female, were all in their twenties to thirties with psychiatric problems and/or an ongoing drug abuse. 3-MeO-PCP was identified with liquid chromatography (LC)/time-of-flight technology and quantified using LC-tandem mass spectrometry. In the clinical case, the concentration of 3-MeO-PCP was 0.14μg/g at admission, 0.08μg/g 2.5h after admission, 0.06μg/g 5h after admission and 0.04μg/g 17h after admission. The half-life of 3-MeO-PCP was estimated to 11h. In the autopsy cases, femoral blood concentrations ranged from 0.05μg/g to 0.38μg/g. 3-MeO-PCP was the sole finding in the case with the highest concentration and the cause of death was established as intoxication with 3-MeO-PCP. In the remaining six autopsy cases, other medications and drugs of abuse were present as well. Despite being scheduled in January 2015, 3-MeO-PCP continues to be abused in Sweden. Exposure to 3-MeO-PCP may cause severe adverse events and even death, especially if the user does not receive life-supporting treatment.

Comments

No comments yet.

Log in to comment